Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Menactra May Require More Data For Approval, Advisory Committee Chair Says

This article was originally published in The Pink Sheet Daily

Executive Summary

"There are a number of issues" related to the meningococcal conjugate vaccine, committee chair Overturf tells National Vaccine Advisory Committee. Sanofi-Aventis says it has not submitted any additional data to FDA on Menactra.

You may also be interested in...



Where’s Menactra? No Word From Sanofi-Aventis As User Fee Date Passes

The estimated user fee deadline for the meningococcal conjugate vaccine was Oct. 18. FDA says the vaccine is not currently a licensed product; Sanofi-Aventis has not announced an action by the agency.

Where’s Menactra? No Word From Sanofi-Aventis As User Fee Date Passes

The estimated user fee deadline for the meningococcal conjugate vaccine was Oct. 18. FDA says the vaccine is not currently a licensed product; Sanofi-Aventis has not announced an action by the agency.

Sanofi-Aventis' Menactra Post-Approval Commitments Should Include Long-Term Safety, Efficacy Data

The quadravalent meningococcal conjugate vaccine displayed immunogenicity and safety similar to Menomune, an FDA Advisory Committee says. Sanofi-Aventis says that preliminary results from a three-year follow-up study suggest that Menactra patients have longer antibody persistence than Menomune.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel